AWM
NPCE icon

Avior Wealth Management’s Neuropace NPCE Stock Holding History

Avior Wealth Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,782
Closed -$19.9K – 1786
2024
Q4 		$19.9K Hold
1,782
– – ﹤0.01% 1411
2024
Q3 		$12.4K Buy
+1,782
New +$13K ﹤0.01% 1495

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avior Wealth Management's NPCE Position: Q1 2025 in Review

Avior Wealth Management sold out of Neuropace (NPCE) in Q1 2025, closing a stake of 1,782 shares — an estimated $19.9K sold.

Avior Wealth Management first reported a position in NPCE in Q3 2024 and held it in 2 quarters. The position peaked at $19.9K in Q4 2024. 90 funds tracked by Wall St. Rank hold NPCE as of Q1 2025.

  • Avior Wealth Management reported no remaining Neuropace position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 1,782 Neuropace shares in Q1 2025, an estimated $19.9K.
  • Avior Wealth Management first reported a position in Neuropace in Q3 2024 and held it in 2 quarters.
  • Avior Wealth Management's Neuropace position peaked at $19.9K in Q4 2024.
  • 90 funds tracked by Wall St. Rank held Neuropace as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.